Sandoz has claimed the first FDA approvals for biosimilars of Amgen’s blockbuster bone disease therapy denosumab, but has not said when it plans to launch them onto the US
A new formulation of Amgen’s cancer treatment Xgeva is the first to be approved in the UK under a new procedure designed to speed up access to new therapies.
Jazz Pharmaceuticals has agreed another pipeline-building deal, this time paying $10 million upfront for rights to a KRAS inhibitor programme from UK biotech Redx Pharma,
Speculation about a takeover play for Cytokinetics isn’t going away, with Amgen the latest company to be linked to the company and its highly-anticipated cardiovascular dr
The FDA has started a priority review of Amgen’s tarlatamab for small cell lung cancer (SCLC), the lead drug in the company’s pipeline of bispecific T-cell engager (BiTE)
Endeavor BioMedicines has completed a third-round financing, raising an impressive $132.5 million to fund trials of its two clinical-stage drug candidates for pulmonary fi
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.